S'abonner

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) - 19/04/18

Doi : 10.1016/j.jaad.2018.01.017 
Eric L. Simpson, MD a, Carsten Flohr, MD, PhD b, Lawrence F. Eichenfield, MD c, Thomas Bieber, MD, PhD, MDRA d, Howard Sofen, MD e, Alain Taïeb, MD f, Ryan Owen, PhD g, Wendy Putnam, PhD g, Marcela Castro, MD g, Kendra DeBusk, PhD g, Chin-Yu Lin, PhD g, Athina Voulgari, PhD h, Karl Yen, MD i, Theodore A. Omachi, MD g,
a Department of Dermatology, School of Medicine, Oregon Health & Science University, Portland, Oregon 
b St. John's Institute of Dermatology, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom 
c Department of Dermatology, University of California San Diego, San Diego, California 
d Department of Dermatology and Allergy, University Medical Center, Bonn, Germany 
e University of California Los Angeles School of Medicine, Los Angeles, California 
f Department of Dermatology and Pediatric Dermatology, Bordeaux Hospital University Center, France 
g Genentech, South San Francisco, California 
h Global Product Development Clinical Science, Roche Products Limited, Welwyn Garden City, United Kingdom 
i Roche, Grenzacherstrasse, Basel, Switzerland 

Correspondence to: Theodore A. Omachi, MD, Genentech, Inc, 1 DNA Way, MS 452a, South San Francisco, CA 94080.Genentech, Inc1 DNA WayMS 452aSouth San FranciscoCA94080

Abstract

Background

Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD).

Objective

We investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment.

Methods

A randomized, placebo-controlled, double-blind, phase 2 study. Adults with moderate-to-severe AD were required to use TCS twice daily and then randomized (1:1:1:1) to lebrikizumab 125 mg single dose, lebrikizumab 250 mg single dose, lebrikizumab 125 mg every 4 weeks for 12 weeks, or placebo every 4 weeks for 12 weeks, after a 2-week TCS run-in. The primary endpoint was percentage of patients achieving Eczema Area and Severity Index (EASI)-50 at week 12.

Results

In total, 209 patients received the study drug. At week 12, significantly more patients achieved EASI-50 with lebrikizumab 125 mg every 4 weeks (82.4%; P = .026) than placebo every 4 weeks (62.3%); patients receiving a single dose of lebrikizumab showed no statistically significant improvements in EASI-50 compared with placebo. Adverse events were similar between groups (66.7% all lebrikizumab vs 66.0% placebo) and mostly mild or moderate.

Limitations

Protocol-mandated twice daily TCS treatment limits our understanding of the efficacy of lebrikizumab as a monotherapy. The short study duration did not enable long-term efficacy or safety evaluations.

Conclusion

When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.

Le texte complet de cet article est disponible en PDF.

Key words : anti-IL-13, atopic dermatitis, EASI, lebrikizumab, pruritus, topical corticosteroids

Abbreviations used : AD, ADIQ, AE, BSA, EASI, IGA, IL-4, IL-13, SCORAD, TCS, VAS


Plan


 Drs Simpson and Flohr contributed to this manuscript equally.
 Funding sources: Funded by Genentech, a member of the Roche Group. Editorial assistance was provided by Wemimo Omotosho, PhD, of MediTech Media, funded by Genentech. Dr Flohr is funded through a National Institute for Health Research (NIHR) Career Development Fellowship (CDF-2014-07-037), and also supported by the NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London.
 Conflicts of interest: Dr Simpson reports grants, personal fees, and nonfinancial support from Roche-Genentech during the conduct of the study; personal fees from AbbVie, Celgene, Dermira, Galderma, LEO Pharma, Menlo Therapeutics, Sanofi Genzyme, and Valeant Pharmaceutical; grants and personal fees from Anacor Pharma, GlaxoSmithKline, and Regeneron Pharmaceuticals; grants from MedImmune, Novartis, Roivant Sciences, Tioga Pharmaceuticals, and Vanda Pharmaceuticals; and grants and personal fees from Eli Lilly outside the submitted work. Dr Flohr reports personal fees from Sanofi Regeneron outside the submitted work. The views expressed are those of the author(s), and not necessarily those of the UK NIHR or the UK Department of Health. Dr Eichenfield reports personal fees and nonfinancial support from Roche-Genentech during the conduction of the study and the following activities: Sanofi Regeneron (investigator, consultant, speaker); Cutanea (consultant); Dermavant (investigator); Eli Lilly (consultant); Galderma (investigator, consultant); Anacor/Pfizer (investigator, consultant); Novartis (consultant); LEO (investigator, consultant); Medimetriks (consultant); and Valeant (investigator, consultant). Dr Bieber has the following declaration of interests: Roche (consultant); Sanofi Regeneron (investigator, consultant, speaker); Eli Lilly (investigator, consultant, speaker); Galderma (investigator, consultant); Pfizer (investigator, consultant); Novartis (investigator, consultant); GlaxoSmithKline (consultant, speaker); LEO (investigator, consultant, speaker); and AbbVie (consultant). Dr Sofen reports personal fees from Genentech during the conduction of the study and personal fees from Regeneron and LEO outside the submitted work. Dr Taïeb has nothing to disclose. Drs Owen, Putnam, DeBusk, Lin, and Omachi are employees of Genentech, a member of the Roche group, and have a patent pending. Dr Yen is an employee of Roche and has a patent pending. Dr Voulgari is an employee of Roche Products Ltd.
 Previously presented: Data from this study were presented at the European Academy of Dermatology and Venereology in Vienna, Austria on October 1, 2016.
 Reprints not available from the authors.


© 2018  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 78 - N° 5

P. 863 - mai 2018 Retour au numéro
Article précédent Article précédent
  • CME examination
| Article suivant Article suivant
  • Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
  • Emma Guttman-Yassky, Patrick M. Brunner, Avidan U. Neumann, Saakshi Khattri, Ana B. Pavel, Kunal Malik, Giselle K. Singer, Danielle Baum, Patricia Gilleaudeau, Mary Sullivan-Whalen, Sharon Rose, Shelbi Jim On, Xuan Li, Judilyn Fuentes-Duculan, Yeriel Estrada, Sandra Garcet, Claudia Traidl-Hoffmann, James G. Krueger, Mark G. Lebwohl

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.